New BONOLIVE® clinical results published in peer reviewed journal. BONOLIVE® increases bone formation biomarkers and improves serum lipid profiles in postmenopausal women with osteopenia
BONOLIVE® is a clinically proven bone health ingredient. The results of a recent 12 month clinical study in 64 postmenopausal women with osteopenia showed significant effects on bone formation biomarkers and maintenance of a balanced bone turnover process and bone mineral density. Furthermore blood lipid profiles significantly improved, as shown by reduced total and LDL cholesterol and triglyceride levels. The results have been published in the Journal of Nutrition, Health & Aging.
BONOLIVE® is a proprietary polyphenol extract from olive leave which supports healthy bones. A recently completed double-blind, placebo-controlled 12 month intervention study in a population of postmenopausal women (n=32 per group) with identified osteopenia has confirmed preclinical data on the protective and balancing effect of BONOLIVE® on the bone remodelling process. Daily intake of BONOLIVE® over 12 months resulted in a consistent and continuous increase in plasma levels of the established bone formation biomarker osteocalcin, as compared to the placebo. This coincided with the maintenance of both the bone balance ratio, a marker for healthy bone remodelling, and bone mineral density in the lumbar spine. In contrast, both parameters deteriorated in the placebo group. Simultaneously, a significant decrease in total and LDL cholesterol and triglyceride levels was noted upon BONOLIVE® intake, suggesting additional health benefits of this highly bioavailable olive polyphenol extract.
The results of this study have been published in the Journal of Nutrition, Health & Aging